HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00018668

Slowed movement and antipsychotic treatment in schizophrenia

About this titleRead the official source — NCT00018668
Medication studyAges 21–70United States
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 21 years to 70 years. Other eligibility criteria applied.

Listed locations
San DiegoSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateOctober 2000
Recruitment status
Completed
Enrollment listed in the registry
Not clearly listed
Sponsor
US Department of Veterans Affairs
Sponsor type
Government agency
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 21 Years to 70 Years
Official registry ID
NCT00018668
Official title
Show the full official title

Psychopharmacologic Aspects of Motor Slowing in Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

San Diego

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is US Department of Veterans Affairs.

Did this study involve medication?

Yes. The study involved medication, including Risperidone, Olanzapine and Quetiapine.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 21 years to 70 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies